Biomarin Pharmaceutical Inc (FRA:BM8)
€ 70 -4.12 (-5.56%) Market Cap: 13.55 Bil Enterprise Value: 13.60 Bil PE Ratio: 72.49 PB Ratio: 2.90 GF Score: 82/100

Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 06:30PM GMT
Release Date Price: €87.94 (-1.28%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with BioMarin. We're very delighted to have BioMarin's new CEO, Alexander Hardy, making a presentation for the company. We're going to follow that with Q&A. If you're in the room, someone will bring you a mic, if you raise your hand for a question, you can also submit them over the portal or you can listen to me ask questions.

But with that, let me pass it over to Alexander.

Alexander Hardy
BioMarin Pharmaceutical Inc. - President, CEO & Director

Thanks very much, Jess. Good morning, everybody. As Jess said, I'm Alexander Hardy. I'm the new CEO of BioMarin. I started in the role, 1st of December 2023. Thank you very much for joining us here today. So this is our safe harbor statement. I'll be making forward-looking comments, so please look at our publicly available materials for more information.

So I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot